Genetic knockdown of HDAC6 inhibits cell proliferation, impairs glioma stem cell activity, and sensitizes glioma cells to temozolomide (TMZ), suggesting that HDAC6 inhibitors such as CAY10603 pose as potential specific (targeted epigenetic) therapies for GBM39,40. Here, HDAC6 is linked to glioma.